AU2011223906B2 - Prognostic marker for cryoglobulinemic vasculitis and B cell malignancies in HCV infected patients - Google Patents

Prognostic marker for cryoglobulinemic vasculitis and B cell malignancies in HCV infected patients Download PDF

Info

Publication number
AU2011223906B2
AU2011223906B2 AU2011223906A AU2011223906A AU2011223906B2 AU 2011223906 B2 AU2011223906 B2 AU 2011223906B2 AU 2011223906 A AU2011223906 A AU 2011223906A AU 2011223906 A AU2011223906 A AU 2011223906A AU 2011223906 B2 AU2011223906 B2 AU 2011223906B2
Authority
AU
Australia
Prior art keywords
hcv
xid
subject
cell
consensus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2011223906A
Other languages
English (en)
Other versions
AU2011223906A1 (en
Inventor
Vincent Agnello
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of AU2011223906A1 publication Critical patent/AU2011223906A1/en
Application granted granted Critical
Publication of AU2011223906B2 publication Critical patent/AU2011223906B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57505—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the blood, e.g. leukaemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G01N33/5767—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis non-A, non-B hepatitis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/686—Anti-idiotype
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/328—Vasculitis, i.e. inflammation of blood vessels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
AU2011223906A 2010-03-01 2011-02-28 Prognostic marker for cryoglobulinemic vasculitis and B cell malignancies in HCV infected patients Ceased AU2011223906B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US30916110P 2010-03-01 2010-03-01
US61/309,161 2010-03-01
PCT/US2011/026455 WO2011109285A2 (en) 2010-03-01 2011-02-28 Prognostic marker for cryoglobulinemic vasculitis and b cell malignancies in hcv infected patients

Publications (2)

Publication Number Publication Date
AU2011223906A1 AU2011223906A1 (en) 2012-09-13
AU2011223906B2 true AU2011223906B2 (en) 2015-06-25

Family

ID=44542788

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2011223906A Ceased AU2011223906B2 (en) 2010-03-01 2011-02-28 Prognostic marker for cryoglobulinemic vasculitis and B cell malignancies in HCV infected patients

Country Status (7)

Country Link
US (3) US9719141B2 (https=)
EP (1) EP2542892A4 (https=)
JP (1) JP6095984B2 (https=)
AU (1) AU2011223906B2 (https=)
BR (1) BR112012021795A2 (https=)
CA (1) CA2791676A1 (https=)
WO (1) WO2011109285A2 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103184216B (zh) * 2011-12-27 2015-03-18 深圳华大基因科技有限公司 用于扩增免疫球蛋白重链cdr3编码序列的引物组合物及其用途
US11781112B2 (en) 2016-03-06 2023-10-10 Kareem Thomas Robinson Method of generating antigen-specific immunological memory in a subject that rejects classical vaccines
RU2642626C1 (ru) * 2016-11-03 2018-01-25 Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) Способ прогнозирования развития криоглобулинемического васкулита у больных хроническим гепатитом с
US11026625B2 (en) 2017-08-08 2021-06-08 Fresenius Medical Care Holdings, Inc. Systems and methods for treating and estimating progression of chronic kidney disease

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20020049A1 (it) 2002-01-30 2003-07-30 Biostrands S R L Frammenti fab di anticorpi monoclonali umani diretti contro la glicoproteina e2 di hcv e dotati di potere neutralizzante in vitro.
US8178303B2 (en) 2003-12-04 2012-05-15 Wake Forest University Health Sciences Increasing the speed of cryoglobulin precipitation
EP1801116A1 (en) 2005-12-21 2007-06-27 F. Hoffmann-La Roche Ag HCV replicon shuttle vectors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DE RE, V. et al., International Journal Cancer, 2000, Vol. 87, pages 211-216 *
KNIGHT, G. B et al, J. Exp. Med, 1993, Vol. 178, pages 1903-1911 *

Also Published As

Publication number Publication date
WO2011109285A2 (en) 2011-09-09
BR112012021795A2 (pt) 2016-05-17
US9719141B2 (en) 2017-08-01
EP2542892A2 (en) 2013-01-09
US20160083801A1 (en) 2016-03-24
JP6095984B2 (ja) 2017-03-15
CA2791676A1 (en) 2011-09-09
WO2011109285A3 (en) 2012-01-19
EP2542892A4 (en) 2013-11-27
US20130052206A1 (en) 2013-02-28
AU2011223906A1 (en) 2012-09-13
CN102859360A (zh) 2013-01-02
JP2013521497A (ja) 2013-06-10
US20180002763A1 (en) 2018-01-04

Similar Documents

Publication Publication Date Title
US11320433B2 (en) Anti-dengue virus NS1 protein monoclonal antibodies
Berentsen Complement activation and inhibition in autoimmune hemolytic anemia: focus on cold agglutinin disease
WO2003080640A1 (en) Lymphatic and blood endothelial cell genes
Asaka et al. Highly susceptible SARS-CoV-2 model in CAG promoter–driven hACE2-transgenic mice
US20180002763A1 (en) Prognostic Marker For Cryoglobulinemic Vasculitis And B Cell Malignancies In HCV Infected Patients
US20150098952A1 (en) Novel therapeutic target and diagnostic marker for asthma and related conditions
WO2017175228A1 (en) Infiltrating immune cell proportions predict anti-tnf response in colon biopsies
Azumagawa et al. Post-vaccination MDEM associated with MOG antibody in a subclinical Chlamydia infected boy
Knight et al. Detection of WA B cells in hepatitis C virus infection: a potential prognostic marker for cryoglobulinemic vasculitis and B cell malignancies
EP2984108B1 (en) Anti-s100a7 antibodies for the treatment and diagnosis of cancer
JP2013021932A (ja) 関節リウマチに対する抗ｉｌ−６受容体抗体療法の有効性の予測方法
KR20180016335A (ko) 항-lps 면역글로불린 치료에 대한 임상 반응의 예측성 생체표지자
CN102859360B (zh) Hcv感染患者中的冷球蛋白血症性血管炎和b细胞恶性肿瘤的预测标志物
JP2007145775A (ja) ノロウイルスｇｉの高感度検出方法
CN119529099B (zh) 一种抗nse蛋白的抗体或其抗原结合片段、肿瘤诊断产品及其应用
CN116333110B (zh) 一种特异性结合afp多肽的结合蛋白、肿瘤诊断试剂盒
US12466876B2 (en) Testis development related protein antibodies
US20230096203A1 (en) Methods for detecting food allergies
WO2005019268A1 (ja) 新規癌抗原に対する抗体
Siukola SPATIAL TRANSCRIPTOMICS OF CELIAC DISEASE SMALL INTESTINE IN DIFFERENT STAGES OF INFLAMMATION
HK40041456A (en) Anti-dengue virus ns1 protein monoclonal antibodies
CN119462932A (zh) 一种抗cd8的抗体或其抗原结合片段、富集cd8+细胞的产品及其应用
Lemann et al. European Society for Paediatric Gastroenterology, Hepatology, and Nutrition Annual Meeting June 3–6, 2009 Budapest, Hungary
RU2020124096A (ru) Биомаркеры иммунной толерантности, индуцированной метотрексатом
Morandi Soluble HLA-G: Are they clinically relevant?

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired